• Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Dividend Stocks Report
No Result
View All Result
Home Stock News

Regeneron CEO says its monoclonal antibodies protect people from Covid for months

by
November 8, 2021
in Stock News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

Nvidia and 5 Other Stocks at High Risk for Short Selling

Some Medicare beneficiaries are surprised with premium surcharges, which can triple premiums. Here’s how to appeal and avoid them

Stock Market Rally Signals It’s No Bear Run; Tesla CEO Elon Musk Not Liable For ‘Funding Secured’ Tweets

COVID Feb 3, 2023: Update on Cases, Hospitalizations and Deaths

Dr. Leonard Schleifer, CEO, Regeneron

Scott Mlyn | CNBC

Regeneron’s monoclonal antibodies grant months of protection from Covid-19 and could be administered to individuals whose immune systems aren’t shielded enough by vaccines, CEO Len Schleifer told CNBC’s “Squawk Box” on Monday.

Schleifer’s comments came after Regeneron released data that indicated its one-dose antibody cocktail cut the risk of catching the virus by nearly 82% for two to eight months. Regeneron’s monoclonals have been administered intravenously to treat up to moderate Covid symptoms during the pandemic and lower the chances for hospitalization in high-risk patients, according to the Food and Drug Administration.

“If you want to protect people on a population level, vaccines are the best way to go – they’re cheap and you can make billions of doses,” Schleifer said. “But our data now indicates that antibodies are the key player in the sense that they are sufficient.”

“You might not need the cellular immunity. It might add something, but antibodies are sufficient based on these data to protect you from getting Covid-19,” he added.

Individuals with immunocompromised conditions could eventually receive Regeneron’s monoclonals up to every five or six months, “and they would be protected just as though they were vaccinated,” Schleifer said. He said the treatment could be administered selectively to those at high risk for Covid complications and essential workers with concerns over immunizing.

But Schleifer noted that he didn’t think Regeneron could produce enough antibodies at an affordable price to use them as widely as vaccines.

“If you’re in the military, or you’re a teacher or you’re on the front line and you legitimately have this fear, maybe this can be offered as an alternative. It’s something we have to discuss,” Schleifer said. “But the data – put the politics aside – the data say that antibodies can protect you from getting Covid-19.”

Regeneron’s antibodies target Covid’s spike protein to prevent the virus from penetrating into cells, according to the FDA. The agency adds that monoclonal antibodies “mimic the immune system’s ability to fight off harmful pathogens.”

Regeneron isn’t the only company to unveil promising Covid treatment data in recent weeks. Pfizer announced Friday that its antiviral coronavirus pill slashes the risk of hospitalization or death by 89% for high-risk adults after combining the treatment with an HIV drug to help it last longer in the body.

Merck and Ridgeback Biotherapeutics also released data in October on an antiviral pill that they said cut Covid hospitalizations and deaths by 50% for patients battling mild or moderate cases.

Next Post

Fed Governor Bowman: The U.S. Housing and Mortgage Market: Risks and Resilience

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Stock News

Nvidia and 5 Other Stocks at High Risk for Short Selling

by
February 4, 2023
0

Nvidia and 5 Other Stocks at High Risk for Short Selling | Barron's Stocks have rallied in recent months, with...

Read more

Nvidia and 5 Other Stocks at High Risk for Short Selling

Stock Market Rally Signals It’s No Bear Run; Tesla CEO Elon Musk Not Liable For ‘Funding Secured’ Tweets

Some Medicare beneficiaries are surprised with premium surcharges, which can triple premiums. Here’s how to appeal and avoid them

COVID Feb 3, 2023: Update on Cases, Hospitalizations and Deaths

J.P. Morgan Pounds the Table on These 2 Reliable Dividend Stocks

The Fed raised interest rates this week. So here’s what you should be earning on your savings account now

Load More

All rights reserved by www.dividendstocksreport.net

  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Home
  • Stock News
  • Privacy Policy
  • Email Whitelisting

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.